Get startedLog in
    Picture of LakeShore Biopharma Co logo

    LSB — LakeShore Biopharma Co Income Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for LakeShore Biopharma Co, fiscal year end - March 31st, CNY millions except per share, conversion factor applied.

    2021
    March 31st
    2022
    March 31st
    2023
    March 31st
    Period Length:12 M12 M12 M
    Source:PROSPECTUSPROSPECTUSPROSPECTUS
    Standards:
    USG
    USG
    USG
    Status:FinalFinalFinal
    Revenue
    Total Revenue257503687
    Cost of Revenue
    Gross Profit197386534
    Selling / General / Administrative Expenses
    Research And Development
    Total Operating Expenses383622827
    Operating Profit-126-119-139
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-174-101-144
    Provision for Income Taxes
    Net Income After Taxes-192-106-145
    Net Income Before Extraordinary Items
    Net Income-192-106-145
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-208-237-283
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-2.24-2.54-3.05
    Dividends per Share